Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs IDEXX Laboratories, Inc. — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.52, while IDEXX Laboratories, Inc. trades at $534.38 (market cap $42.65B). The key difference: State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| BIL | IDXX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $766.68 |
52-Week Low | $91.27 | $514.61 |
Market Cap | — | $42.65B |
Enterprise Value | — | $43.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIL trades at $91.50 with no recent price movement. Technical indicators show a bearish trend, with moving averages signaling sell pressure and oscillators neutral. The ETF maintains consistent dividend payments of $0.27 per share. Market sentiment is influenced by Federal Reserve rate hike speculation and competition among cash ETFs, as noted in recent financial news.
The outlook for BIL hinges on interest rate trends, with potential upside if the Fed hikes rates, boosting short-term Treasury yields. Risks include prolonged low-rate environments and investor shifts to higher-yielding alternatives. Current technical weakness suggests caution, but the ETF's stability and dividends offer defensive appeal in volatile markets.
IDXX trades at $564.09, up 0.09% with neutral technical signals. The stock shows strong fundamentals with revenue growth to $4.3B in 2025 and consistent earnings beats. Analyst consensus is bullish (59% Buy) with improving cash flow trends. Recent news highlights AI integration in medical devices and upcoming Q2 2026 earnings.
Outlook remains positive driven by innovation and market leadership in pet healthcare. Risks include high valuation multiples and competitive pressures. Institutional sentiment supports growth, but investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
